Otsuka and Proteus® Announce the First U.S. FDA Approval of a Digital Medicine System: Abilify MyCite® (aripiprazole tablets with sensor)


Publication Title
Proteus Digital Health
Publication/Creation Date
November 14 2017
Creators/Contributors
Proteus Digital Health (creator)
Otsuka Pharmaceutical (creator)
Food And Drug Administration (FDA) (contributor)
Media Type
Press Release
Persuasive Intent
Advertisement
Description
From the Press Release: 

ABILIFY MYCITE (aripiprazole tablets with sensor) is a drug-device combination product comprised of Otsuka’s oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. The ABILIFY MYCITE System includes: ABILIFY MYCITE, the MYCITE® Patch (wearable sensor); the MYCITE APP (a smartphone application); and web-based portals for healthcare providers and caregivers.

The system records medication ingestion and communicates it to the patient and healthcare provider. In addition, it can collect data on activity level, as well as self-reported rest and mood which, with patient consent, can be shared with the healthcare provider and selected members of the family and care team.
HCI Platform
Ingestible
Discursive Type
Inventions
Location on Body
Digestive Tract, Stomach, Skin
Source
http://www.proteus.com/press-releases/otsuka-and-proteus-announce-the-first-us-fda-approval-of-a-digital-medicine-system-abilify-mycite/

Date archived
March 13 2018
Last edited
October 19 2018
How to cite this entry
Proteus Digital Health, Otsuka Pharmaceutical. (November 14 2017). "Otsuka and Proteus® Announce the First U.S. FDA Approval of a Digital Medicine System: Abilify MyCite® (aripiprazole tablets with sensor)". Proteus Digital Health. Fabric of Digital Life. https://fabricofdigitallife.com/index.php/Detail/objects/2848